Lion Point Capital LP Has $2.42 Million Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Lion Point Capital LP reduced its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 38.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,025,806 shares of the company's stock after selling 628,348 shares during the period. Milestone Pharmaceuticals accounts for approximately 12.7% of Lion Point Capital LP's holdings, making the stock its 2nd largest holding. Lion Point Capital LP owned about 1.92% of Milestone Pharmaceuticals worth $2,421,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Jones Financial Companies Lllp lifted its holdings in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock worth $26,000 after acquiring an additional 10,000 shares in the last quarter. National Bank of Canada FI increased its position in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after acquiring an additional 11,600 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Milestone Pharmaceuticals during the fourth quarter worth approximately $73,000. XTX Topco Ltd acquired a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $80,000. Finally, Northern Trust Corp boosted its stake in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after buying an additional 30,772 shares during the period. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock traded up $0.07 during mid-day trading on Friday, hitting $1.22. 875,896 shares of the stock were exchanged, compared to its average volume of 890,671. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The company has a market capitalization of $65.23 million, a P/E ratio of -1.51 and a beta of 0.86. The company has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $1.71. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Sell-side analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. TD Securities downgraded shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Friday, March 28th. TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, Cowen downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $17.00.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.